Anna Norhammar1,2, Johan Bodegård3, Thomas Nyström4, Marcus Thuresson5, Jan W Eriksson6, David Nathanson4. 1. Cardiology Unit, Department of Medicine, Solna, Karolinska Institutet, Karolinska University Hospital, 171 76, Stockholm, Sweden. anna.norhammar@ki.se. 2. Capio St Görans Hospital, Stockholm, Sweden. anna.norhammar@ki.se. 3. Astra Zeneca Nordic-Baltic, Södertälje, Sweden. 4. Department of Clinical Science and Education, Division of Internal Medicine, Unit for Diabetes Research, Karolinska Institutet, Södersjukhuset, Stockholm, Sweden. 5. Statisticon AB, Uppsala, Sweden. 6. Department of Medical Sciences, Clinical Diabetes and Metabolism, Uppsala University, Uppsala, Sweden.
Abstract
AIMS/HYPOTHESIS: The global diabetes epidemic affects countries differently. We aimed to describe trends in the incidence and prevalence of type 2 diabetes mellitus requiring glucose-lowering treatment, together with associated life expectancy and risks of significant clinical complications. METHODS: Data on patients with type 2 diabetes who filled a prescription for any glucose-lowering drug (GLD) during the period 2006-2013 were extracted from the Swedish Prescribed Drug Register, Cause of Death Register and Swedish National Patient Register. RESULTS: In 2013, the prevalence of GLD-treated type 2 diabetes was 4.4% (n = 352,436) and the incidence was 399 per 100,000 population (n = 30,620). During 2006-2013, the prevalence increased by 61% while the incidence remained relatively stable; the prevalence of cardiovascular disease (CVD, 34% in 2013) and microvascular disease (16% in 2013) was also stable. Insulin use increased by 29% while sulfonylurea use declined by 55%. Compared with the general population, patients with type 2 diabetes had increased risk of myocardial infarction, stroke and all-cause mortality, with age-standardised risks of ∼1.7-, 1.5- and 1.3-fold, respectively. These risks declined over time. Life-years lost due to diabetes was most pronounced at younger ages and improved in women over time from 2006 to 2013. CONCLUSIONS/ INTERPRETATION: The prevalence of type 2 diabetes requiring GLD treatment in Sweden increased substantially in recent years, while the incidence remained stable. Use of sulfonylurea declined while insulin use increased. The high prevalence of diabetes-related comorbidities, increased risk of complications and life-years lost highlights the need for optimised and new preventive strategies in patients with type 2 diabetes.
AIMS/HYPOTHESIS: The global diabetes epidemic affects countries differently. We aimed to describe trends in the incidence and prevalence of type 2 diabetes mellitus requiring glucose-lowering treatment, together with associated life expectancy and risks of significant clinical complications. METHODS: Data on patients with type 2 diabetes who filled a prescription for any glucose-lowering drug (GLD) during the period 2006-2013 were extracted from the Swedish Prescribed Drug Register, Cause of Death Register and Swedish National Patient Register. RESULTS: In 2013, the prevalence of GLD-treated type 2 diabetes was 4.4% (n = 352,436) and the incidence was 399 per 100,000 population (n = 30,620). During 2006-2013, the prevalence increased by 61% while the incidence remained relatively stable; the prevalence of cardiovascular disease (CVD, 34% in 2013) and microvascular disease (16% in 2013) was also stable. Insulin use increased by 29% while sulfonylurea use declined by 55%. Compared with the general population, patients with type 2 diabetes had increased risk of myocardial infarction, stroke and all-cause mortality, with age-standardised risks of ∼1.7-, 1.5- and 1.3-fold, respectively. These risks declined over time. Life-years lost due to diabetes was most pronounced at younger ages and improved in women over time from 2006 to 2013. CONCLUSIONS/ INTERPRETATION: The prevalence of type 2 diabetes requiring GLD treatment in Sweden increased substantially in recent years, while the incidence remained stable. Use of sulfonylurea declined while insulin use increased. The high prevalence of diabetes-related comorbidities, increased risk of complications and life-years lost highlights the need for optimised and new preventive strategies in patients with type 2 diabetes.
Entities:
Keywords:
Cardiovascular disease; Glucose-lowering therapy; Incidence; Life expectancy; Mortality; Prevalence; Type 2 diabetes
Authors: L Monesi; M Baviera; I Marzona; F Avanzini; G Monesi; A Nobili; M Tettamanti; L Cortesi; E Riva; I Fortino; A Bortolotti; G Fontana; L Merlino; M C Roncaglioni Journal: Diabet Med Date: 2012-03 Impact factor: 4.359
Authors: Edward W Gregg; Xiaohui Zhuo; Yiling J Cheng; Ann L Albright; K M Venkat Narayan; Theodore J Thompson Journal: Lancet Diabetes Endocrinol Date: 2014-08-12 Impact factor: 32.069
Authors: M Lind; L A Garcia-Rodriguez; G L Booth; L Cea-Soriano; B R Shah; G Ekeroth; L L Lipscombe Journal: Diabetologia Date: 2013-10-11 Impact factor: 10.122
Authors: Steven A Grover; Mohammed Kaouache; Philip Rempel; Lawrence Joseph; Martin Dawes; David C W Lau; Ilka Lowensteyn Journal: Lancet Diabetes Endocrinol Date: 2014-12-05 Impact factor: 32.069
Authors: Hanne Strøm; Randi Selmer; Kåre I Birkeland; Henrik Schirmer; Tore Julsrud Berg; Anne Karen Jenum; Kristian Midthjell; Christian Berg; Lars Christian Stene Journal: BMC Public Health Date: 2014-05-29 Impact factor: 3.295
Authors: Anna Norhammar; Johan Bodegard; Thomas Nyström; Marcus Thuresson; Klas Rikner; David Nathanson; Jan W Eriksson Journal: Diabetes Obes Metab Date: 2019-08-26 Impact factor: 6.577
Authors: Mikhail Kosiborod; Matthew A Cavender; Alex Z Fu; John P Wilding; Kamlesh Khunti; Reinhard W Holl; Anna Norhammar; Kåre I Birkeland; Marit Eika Jørgensen; Marcus Thuresson; Niki Arya; Johan Bodegård; Niklas Hammar; Peter Fenici Journal: Circulation Date: 2017-05-18 Impact factor: 29.690
Authors: Frederik Persson; Thomas Nyström; Marit E Jørgensen; Bendix Carstensen; Hanne L Gulseth; Marcus Thuresson; Peter Fenici; David Nathanson; Jan W Eriksson; Anna Norhammar; Johan Bodegard; Kåre I Birkeland Journal: Diabetes Obes Metab Date: 2017-09-08 Impact factor: 6.577
Authors: Zoltán Kiss; György Rokszin; Zsolt Abonyi-Tóth; György Jermendy; Péter Kempler; Dániel Aradi; István Wittmann Journal: Cardiovasc Diabetol Date: 2018-07-27 Impact factor: 9.951